USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NAVIDEA BIOPHARMACEUTICALS, INC.
Address:
5600 Blazer Parkway, Suite 200
DUBLIN, OH 43017
Phone:
N/A
URL:
EIN:
311080091
DUNS:
131891467
Number of Employees:
51
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $725,855.00 3

Award List:

CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$315,217.00
Agency:
HHS
Principal Investigator:
Frederick O. Cope – 614-822-2320
Abstract:
DESCRIPTION (provided by applicant): After an interim period of inactivity based on a select alternative commercial focus, and after consultation with the FDA, Neoprobe Corporation is rapidly reinitiating efforts to develop and commercialize 125Iodine-labeled HuCC49 CH2 anti-Tumor Associated… More

Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$258,824.00
Agency:
HHS
Principal Investigator:
Frederick O. Cope – 617-822-2330
Abstract:
DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing 18F-AZD4694 as a diagnostic imaging agent to be used with PET scans to directly visualize beta amyloid (A ) deposits in the brains of living patients. A deposits in the brains of patients with dementia are diagnostic for… More

A peripheral diagnostic biomarker for Major Depressive Disorder

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$151,814.00
Agency:
HHS
Principal Investigator:
Frederick O. Cope – 614-822-2330
Abstract:
DESCRIPTION (provided by applicant): Navidea Biopharmaceuticals is developing [18F]NAV4694 as a diagnostic imaging agent that can be used to visualize beta-amyloid (A) plaques in the brains of living individuals. Alzheimer's disease is the leading cause ofdementia. All patients with dementia… More